Advertisement
CTSO vs LUNG
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CTSO is a Hold and LUNG is a Buy.
Momentum Indicator for CTSO turns positive, indicating new upward trend
CTSO saw its Momentum Indicator move above the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 107 similar instances where the indicator turned positive. In 85 of the 107 cases, the stock moved higher in the following days. The odds of a move higher are at 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for CTSO just turned positive on October 08, 2026. Looking at past instances where CTSO's MACD turned positive, the stock continued to rise in 39 of 50 cases over the following month. The odds of a continued upward trend are 78%.
Following a +26.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where CTSO advanced for three days, in 188 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTSO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
CTSO broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CTSO entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CTSO's P/B Ratio (-20.140) is slightly lower than the industry average of (4.142). P/E Ratio (-0.828) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.483) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. CTSO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTSO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
LUNG's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for LUNG turned positive on October 20, 2026. Looking at past instances where LUNG's MACD turned positive, the stock continued to rise in 43 of 51 cases over the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on LUNG as a result. In 65 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
LUNG moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LUNG crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Following a +9.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where LUNG advanced for three days, in 214 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for LUNG moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 30 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 56 cases where LUNG's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LUNG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
LUNG broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LUNG entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.805) is normal, around the industry mean (4.142). P/E Ratio (-2.226) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.932) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. LUNG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LUNG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CTSO | LUNG | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 43 | 46 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 22 Undervalued | 28 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 50 | 34 | |
P/E GROWTH RATING 1..100 | 100 | 97 | |
SEASONALITY SCORE 1..100 | 50 | 3 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CTSO's Valuation (22) in the Medical Specialties industry is in the same range as LUNG (28) in the null industry. This means that CTSO’s stock grew similarly to LUNG’s over the last 12 months.
CTSO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as LUNG (100) in the null industry. This means that CTSO’s stock grew similarly to LUNG’s over the last 12 months.
LUNG's SMR Rating (98) in the null industry is in the same range as CTSO (100) in the Medical Specialties industry. This means that LUNG’s stock grew similarly to CTSO’s over the last 12 months.
LUNG's Price Growth Rating (34) in the null industry is in the same range as CTSO (50) in the Medical Specialties industry. This means that LUNG’s stock grew similarly to CTSO’s over the last 12 months.
LUNG's P/E Growth Rating (97) in the null industry is in the same range as CTSO (100) in the Medical Specialties industry. This means that LUNG’s stock grew similarly to CTSO’s over the last 12 months.
| CTSO | LUNG | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 89% |
| Momentum ODDS (%) | 2 days ago 79% | 2 days ago 81% |
| MACD ODDS (%) | 3 days ago 78% | 2 days ago 84% |
| TrendWeek ODDS (%) | 2 days ago 78% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 76% | 2 days ago 77% |
| Advances ODDS (%) | 3 days ago 78% | 8 days ago 81% |
| Declines ODDS (%) | 17 days ago 88% | 10 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 88% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CTSO’s FA Score shows that 1 FA rating(s) are green while LUNG’s FA Score has 1 green FA rating(s).
- CTSO’s FA Score: 1 green, 4 red.
- LUNG’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CTSO’s TA Score shows that 3 TA indicator(s) are bullish while LUNG’s TA Score has 5 bullish TA indicator(s).
- CTSO’s TA Score: 3 bullish, 4 bearish.
- LUNG’s TA Score: 5 bullish, 5 bearish.
Price Growth
CTSO (@Medical/Nursing Services) experienced а +27.75% price change this week, while LUNG (@Medical/Nursing Services) price change was +2.94% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.89%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was -1.76%.
Reported Earning Dates
CTSO is expected to report earnings on Nov 12, 2026.
LUNG is expected to report earnings on Feb 24, 2027.
Industries' Descriptions
@Medical/Nursing Services (-2.89% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
CTSO and
Correlation & Price change
A.I.dvisor tells us that CTSO and TMDX have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CTSO and TMDX's prices will move in lockstep.
| Ticker / NAME | Correlation To CTSO | 1D Price Change % | ||
|---|---|---|---|---|
| CTSO | 100% | -0.51% | ||
| TMDX - CTSO | 25% Poorly correlated | -3.03% | ||
| LUNG - CTSO | 25% Poorly correlated | N/A | ||
| AZTA - CTSO | 23% Poorly correlated | -1.15% | ||
| CSTL - CTSO | 23% Poorly correlated | +0.12% | ||
| CRL - CTSO | 23% Poorly correlated | -2.13% | ||
More | ||||
LUNG and
Correlation & Price change
A.I.dvisor indicates that over the last year, LUNG has been loosely correlated with SRTS. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if LUNG jumps, then SRTS could also see price increases.
| Ticker / NAME | Correlation To LUNG | 1D Price Change % | ||
|---|---|---|---|---|
| LUNG | 100% | N/A | ||
| SRTS - LUNG | 57% Loosely correlated | +3.77% | ||
| BAX - LUNG | 53% Loosely correlated | +0.04% | ||
| ALGN - LUNG | 52% Loosely correlated | N/A | ||
| UTMD - LUNG | 32% Poorly correlated | -0.01% | ||
| KIDS - LUNG | 31% Poorly correlated | -1.50% | ||
More | ||||